Nuveen Asset Management, LLC Atreca, Inc. Transaction History

Nuveen Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $233,599 - $486,664	-149,743 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.61 - $5.2 $2,070 - $6,687	1,286 Added 0.87%	149,743 $509,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $66,328 - $145,368	23,111 Added 18.44%	148,457 $446,000
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $45,687 - $84,396	9,305 Added 8.02%	125,346 $789,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $1,227 - $2,166	-157 Reduced 0.14%	116,041 $989,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $103,740 - $154,333	7,980 Added 7.37%	116,198 $1.78 Million
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $11,362 - $14,902	872 Added 0.81%	108,218 $1.75 Million
Q3 2020 Nov 16, 2020	BUY	$12.67 - $23.19 $229,504 - $420,063	18,114 Added 20.3%	107,346 $1.5 Million
Q2 2020 Aug 14, 2020	SELL	$12.52 - $23.45 $619,301 - $1.16 Million	-49,465 Reduced 35.66%	89,232 $1.9 Million
Q1 2020 May 14, 2020	BUY	$11.4 - $27.28 $1.4 Million - $3.35 Million	122,797 Added 772.31%	138,697 $2.3 Million
Q4 2019 Feb 14, 2020	BUY	$9.68 - $18.67 $56,056 - $108,117	5,791 Added 57.29%	15,900 $246,000
Q3 2019 Nov 14, 2019	BUY	$10.42 - $22.04 $105,335 - $222,802	10,109 New	10,109 $124,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.